August 10, 2021 in Newsroom

MOLLI™ Adopted for Use by Sunnybrook Hospital, Replaces Radioactive Seed Localization

TORONTO HOSPITAL BECOMES THE FIRST HOME TO THE CANADIAN-BASED, WIRE-FREE BREAST CANCER LOCALIZATION TECHNOLOGY MOLLI™, a homegrown, wire-free, radiation-free technology for breast cancer surgery, will replace the radioactive seed localization process being used at Sunnybrook Hospital. The newly developed tool, which was recently approved for use by Health Canada, enables radiologists to quickly and accurately localize lesions. The technology facilitates more efficient removal by surgeons, and results in a better overall experience for patients.  “MOLLI was created at the Louise…
Read More
May 20, 2021 in Newsroom

MOLLI Health Canada Licence

HEALTH CANADA APPROVES MOLLI™ AS THE FIRST CANADIAN-MADE WIRE-FREE LOCALIZATION TECHNOLOGY FOR BREAST CANCER SURGERY #MadeInCanada MOLLI provides breast cancer patients with a better experience over traditional wire and other lesion localization options; the new device helps surgeons remove lesions more efficiently with accuracy and specificity. TORONTO, ON May 20th, 2021 /PRWeb/ -- MOLLI Surgical Inc. today announces Health Canada licensing for Canadian-based MOLLI™, a new wire-free localization technology for breast cancer surgery. The technology helps radiologists mark lesions quickly…
Read More
April 29, 2021 in Newsroom

MOLLI 510(k) Clearance

MOLLI SURGICAL INC. ANNOUNCES FDA CLEARANCE FOR MOLLI™, A WIRE-FREE LOCALIZATION TECHNOLOGY FOR BREAST CANCER SURGERY   MOLLI provides breast cancer patients with a better experience over traditional wire and other lesion localization options; the new device helps surgeons remove lesions more efficiently with accuracy and specificity.   CHICAGO, IL, April 29, 2021 /PRWeb/ — MOLLI Surgical Inc. today announces U.S. Food and Drug Administration clearance for MOLLI™, a new wire-free localization technology for breast cancer surgery. The new technology helps radiologists mark lesions quickly and…
Read More